Official registry condition

Congenital Hyperinsulinism peptide trials

3 selected ClinicalTrials.gov records carrying the official condition label Congenital Hyperinsulinism. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

3 selected records.

Connected peptides

1 profiles.

Registry update years

2023–2026 in selected records.

Indication intelligence

Selected evidence landscape

Connected profiles1

Exact peptide identities attached to retained registry observations carrying this condition label.

Trial phases2

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses1

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 2 selected PubMed records and 1 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Congenital Hyperinsulinism unless their own cited source says so.

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT03777176

PeptideScanner retained ClinicalTrials.gov record NCT03777176 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-12-13, and PeptideScanner's reviewed identity mapping was dasiglucagon.

PeptideScanner change date
November 16, 2026
Cited source date
December 13, 2023
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03941236

PeptideScanner retained ClinicalTrials.gov record NCT03941236 at 2026-11-16T01:42:39.027Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was dasiglucagon.

PeptideScanner change date
November 16, 2026
Cited source date
August 3, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04172441

PeptideScanner retained ClinicalTrials.gov record NCT04172441 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-03-14, and PeptideScanner's reviewed identity mapping was dasiglucagon.

PeptideScanner change date
November 16, 2026
Cited source date
March 14, 2025
Evidence lane
Clinical trials

Attributed registry records

Selected records

All trial facets →